Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia
Open Access
- 5 September 2025
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 157, 108089
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 27 references indexed in Scilit:
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology, 2024
- Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapyLeukemia Research, 2023
- Real-world Management of CML: Outcomes and Treatment PatternsCurrent Hematologic Malignancy Reports, 2023
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBLLeukemia, 2023
- Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemiaAnnals of Hematology, 2022
- Chronic Myeloid Leukemia: Modern therapies, current challenges and future directionsBlood Reviews, 2021
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practiceBlood Cancer Journal, 2021
- The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinaseLeukemia Research, 2020
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureNew England Journal of Medicine, 2019
- Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034American Journal of Hematology, 2016